Search results for "harm"

showing 10 items of 13866 documents

Dopaminergic-GABAergic interplay and alcohol binge drinking

2019

© 2019 Elsevier Ltd The dopamine D 3 receptor (D 3 R), in the nucleus accumbens (NAc), plays an important role in alcohol reward mechanisms. The major neuronal type within the NAc is the GABAergic medium spiny neuron (MSN), whose activity is regulated by dopaminergic inputs. We previously reported that genetic deletion or pharmacological blockade of D 3 R increases GABA A α6 subunit in the ventral striatum. Here we tested the hypothesis that D 3 R-dependent changes in GABA A α6 subunit in the NAc affect voluntary alcohol intake, by influencing the inhibitory transmission of MSNs. We performed in vivo and ex vivo experiments in D 3 R knockout (D 3 R −/− ) mice and wild type littermates (D 3 …

0301 basic medicineMalemedicine.medical_specialtyDopaminergic-GABAergicSettore BIO/09 - FISIOLOGIAAlpha6 subunit; Dopamine D3 receptor; Ethanol; Furosemide (PubChem CID: 3440); GABA(A)receptor; Nucleus accumbens; Ro 15-4513; Ro 15-4513 (PubChem CID: 5081); SB 277011A (PubChem CID: 75358288)Alpha6 subunitNucleus accumbensMedium spiny neuronInhibitory postsynaptic potentialNucleus AccumbensBinge Drinking03 medical and health sciencesMiceDopamine D3 receptor0302 clinical medicineDopamine receptor D3Internal medicinemedicineAnimalsFurosemide (PubChem CID: 3440)Nucleus accumbenPharmacology & PharmacyRNA MessengerRo 15-4513GABAergic NeuronsSB 277011A (PubChem CID: 75358288).PharmacologyMice KnockoutEthanolGABAA receptorChemistryDopaminergicAntagonistReceptors Dopamine D3Receptors GABA-ARo 15-4513 (PubChem CID: 5081)GABA(A)receptor3. Good healthProtein Subunits030104 developmental biologyEndocrinologynervous systemGene Expression Regulation030220 oncology & carcinogenesisGABAergicNucleus accumbensSB 277011A (PubChem CID: 75358288)
researchProduct

Anxiolytic effects of muscarinic acetylcholine receptors agonist oxotremorine in chronically stressed rats and related changes in BDNF and FGF2 level…

2017

Rationale: In depressive disorders, one of the mechanisms proposed for antidepressant drugs is the enhancement of synaptic plasticity in the hippocampus and cerebral cortex. Previously, we showed that the muscarinic acetylcholine receptor (mAChR) agonist oxotremorine (Oxo) increases neuronal plasticity in hippocampal neurons via FGFR1 transactivation. Objectives: Here, we aimed to explore (a) whether Oxo exerts anxiolytic effect in the rat model of anxiety-depression-like behavior induced by chronic restraint stress (CRS), and (b) if the anxiolytic effect of Oxo is associated with the modulation of neurotrophic factors, brain-derived neurotrophic factor (BDNF) and fibroblast growth factor-2…

0301 basic medicineMalemedicine.medical_specialtyElevated plus mazemedicine.drug_classBehavioral testPrefrontal CortexHippocampal formationAnxietyMuscarinic AgonistsAnxiolyticHippocampus03 medical and health sciences0302 clinical medicineInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineMuscarinic acetylcholine receptor M4AnimalsElevated plus maze testRats WistarPrefrontal cortexmAChRChronic restraint streForced swimming testPharmacologyNeuronsChemistryBrain-Derived Neurotrophic FactorOxotremorineCerebral cortexRats030104 developmental biologymedicine.anatomical_structureEndocrinologyAnti-Anxiety AgentsCerebral cortexFibroblast Growth Factor 2Anxiety; Behavioral test; Cerebral cortex; Chronic restraint stress; Elevated plus maze test; Forced swimming test; mAChR; Neurotrophins; Novelty suppressed feeding test; PharmacologyNeurotrophinNovelty suppressed feeding testNeuroscience030217 neurology & neurosurgeryStress Psychologicalmedicine.drugPsychopharmacology
researchProduct

Mechanisms involved in the increased sensitivity of the rabbit basilar artery to atrial natriuretic peptide in diabetes.

2017

Atrial natriuretic peptide (ANP) is a vasodilator with significant regional differences and controversial effects in the cerebral circulation, a vascular bed particularly prone to diabetes-induced complications. The present study has investigated how alloxan-induced diabetes modifies the mechanisms involved in the response of the rabbit basilar artery to ANP. ANP (10(-12) -10(-7) M) relaxed precontracted basilar arteries, with higher potency in diabetic than in control rabbits. In arteries from both groups of animals, endothelium removal reduced ANP-induced relaxations. Inhibition of NO-synthesis attenuated ANP-induced relaxation but this attenuation was lower in diabetic than in control ra…

0301 basic medicineMalemedicine.medical_specialtyEndotheliummedicine.drug_classRabbit basilar arteryVasodilationProstanoidsNitric OxidePotassium channelsDiabetes Mellitus ExperimentalGlibenclamide03 medical and health sciencesCerebral circulationAtrial natriuretic peptidemedicine.arteryInternal medicinemedicineBasilar arteryNatriuretic peptideAnimalsAtrial natriuretic peptidePharmacologyDose-Response Relationship Drugbusiness.industryDiabetesNitric oxideIberiotoxin030104 developmental biologyEndocrinologymedicine.anatomical_structureBasilar Arterycardiovascular systemProstaglandinsRabbitsbusinessReceptors Atrial Natriuretic Factorhormones hormone substitutes and hormone antagonistsAtrial Natriuretic Factormedicine.drugEuropean journal of pharmacology
researchProduct

Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation.

2017

The Mas receptor is involved in the angiotensin (Ang)-(1-7) vasodilatory actions by increasing nitric oxide production (NO). We have previously demonstrated an increased production of Ang-(1-7) in human umbilical vein endothelial cells (HUVEC) exposed to estradiol (E2), suggesting a potential cross-talk between E2 and the Ang-(1-7)/Mas receptor axis. Here, we explored whether the vasoactive response and NO-related signalling exerted by E2 are influenced by Mas. HUVEC were exposed to 10nM E2 for 24h in the presence or absence of the selective Mas receptor antagonist A779, and the estrogen receptor (ER) antagonist ICI182780 (ICI). E2 increased Akt and endothelial nitric oxide synthase (eNOS) …

0301 basic medicineMalemedicine.medical_specialtyEstrogen receptorVasodilationNitric OxideBiochemistryProto-Oncogene MasUmbilical veinNitric oxideReceptors G-Protein-Coupled03 medical and health scienceschemistry.chemical_compoundMiceEnosInternal medicineProto-Oncogene ProteinsmedicineHuman Umbilical Vein Endothelial CellsAnimalsHumansProtein kinase BPharmacologybiologyAntagonistbiology.organism_classificationMice Inbred C57BLVasodilation030104 developmental biologyEndocrinologychemistryReceptors EstrogenMyographBiochemical pharmacology
researchProduct

Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine‐N‐oxide

2018

Aims Trimethylamine-N-oxide (TMAO) is a novel cardiovascular risk marker. We explored the association of commonly used cardiovascular medications with TMAO levels in patients and validated the identified associations in mice. Methods Detailed history of drug treatment was recorded in 300 patients with cardiovascular disease without diabetes in an observational, cross-sectional study. Animal study was performed in CD1 mice. Results Median plasma TMAO (interquartile range) level was 2.144 (1.570-3.104) μmol l-1 . Among nine cardiovascular drug groups, the use of loop diuretics (0.510 ± 0.296 in users vs. 0.336 ± 0.272 in nonusers, P = 0.008) and mineralocorticoid receptor antagonists (0.482 ±…

0301 basic medicineMalemedicine.medical_specialtyOrganic anion transporter 1medicine.drug_classTrimethylamine N-oxide030204 cardiovascular system & hematologyKidneyExcretion03 medical and health scienceschemistry.chemical_compoundMethylaminesMice0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsInternal medicineBlood plasmamedicineAnimalsHumansPharmacology (medical)AgedPharmacologybiologyChemistryArea under the curveFurosemideCardiovascular AgentsHeartOriginal ArticlesLoop diureticMiddle AgedProbenecid030104 developmental biologyEndocrinologyCross-Sectional StudiesLiverCardiovascular Diseasesbiology.proteinFemaleBiomarkersmedicine.drug
researchProduct

Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats

2020

Abstract Lorcaserin, which is a selective agonist of serotonin2C receptors (5-HT2CRs), is a new FDA-approved anti-obesity drug that has also shown therapeutic promise in other brain disorders, such as addiction and epilepsy. The modulation of dopaminergic function might be critical in the therapeutic effect of lorcaserin, but its exact effect is unknown. Here, we studied the effect of the peripheral administration of lorcaserin on the ventral tegmental area (VTA), the substantia nigra pars compacta (SNc) dopaminergic neural activity, dopamine (DA) dialysis levels in the nucleus accumbens and striatum and on DA tissue levels in 29 different rat brain regions. Lorcaserin (5–640 μg/kg, i.v.) m…

0301 basic medicineMalemedicine.medical_specialtySerotoninDopamineSubstantia nigraStriatumNucleus accumbensSettore BIO/09 - FisiologiaLorcaserinIntracerebral microdialysisRats Sprague-DawleyDose-Response Relationship03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineSingle cell extracellular recordingsRewardDopamineInternal medicineReceptor Serotonin 5-HT2CmedicineAnimals5-HT2CObesityPharmacologyDose-Response Relationship DrugPars compactaChemistryDopaminergic NeuronsDopaminergicBrainNeurochemistryBenzazepinesSerotonin2C receptorRatsVentral tegmental area030104 developmental biologyEndocrinologymedicine.anatomical_structurenervous systemSprague-DawleyDrugIntracerebral microdialysis; Neurochemistry; Obesity; Reward; Serotonin2C receptor; Single cell extracellular recordings; Animals; Benzazepines; Brain; Dopamine; Dopaminergic Neurons; Dose-Response Relationship Drug; Male; Rats; Rats Sprague-Dawley; Receptor Serotonin 5-HT2C; Serotonin 5-HT2 Receptor AgonistsIntracerebral microdialysi030217 neurology & neurosurgerySerotonin 5-HT2 Receptor Agonistsmedicine.drugReceptor
researchProduct

Cyclophosphamide plus vincristine and prednisone in the treatment of severe pemphigus vulgaris refractory to conventional therapy

1992

Five patients with severe pemphigus vulgaris refractory to conventional therapy with azathioprine and corticosteroids were treated with cyclophosphamide, vincristine and prednisone. One patient was not evaluable, while the remaining four patients showed a complete response. Duration of response was in the range of 13-94 months. Toxicity was mainly represented by alopecia, myelosuppression and gastrointestinal side-effects such as nausea/vomiting. Although cyclophosphamide and vincristine may induce severe side-effects, this association may be useful in controlling severe disease resistant to previous conventional therapies.

0301 basic medicineMalemedicine.medical_specialtyVincristineCyclophosphamideAdolescentNausea030106 microbiologyAzathioprinemacromolecular substancesGastroenterology03 medical and health sciences0302 clinical medicineRefractoryPrednisoneInternal medicinemedicineHumansPharmacology (medical)CyclophosphamideAgedPharmacologybusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseInfectious DiseasesOncologyVincristine030220 oncology & carcinogenesisVomitingPrednisoneDrug Therapy CombinationFemalemedicine.symptombusinessPemphigusmedicine.drug
researchProduct

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Acute and chronic nicotine exposures differentially affect central serotonin 2A receptor function : focus on the lateral habenula

2020

Nicotine addiction is a serious public health problem causing millions of deaths worldwide. Serotonin (5-hydroxytryptamine

0301 basic medicineMalenucleus accumbensdorsal raphe nucleusmedicine.medical_treatmentstriatumPharmacologySmoking cessationSettore BIO/09 - FisiologiaSerotonin -- Receptorslcsh:ChemistryNicotineRats Sprague-DawleyNicotine addiction -- Treatment0302 clinical medicine5-HT2Asubstantia nigra pars compactaReceptor Serotonin 5-HT2Adentate gyruslcsh:QH301-705.5Spectroscopymedia_commonNeuronsGeneral MedicineDorsal raphe nucleu5-HT<sub>2C</sub>RComputer Science ApplicationsVentral tegmental areamedicine.anatomical_structuredepressionaddiction5-HT2CR; Addiction; Dentate gyrus; Depression; Dorsal raphe nucleus; Medial prefrontal cortex; Nucleus accumbens; Striatum; Substantia nigra pars compacta; Ventral tegmental area; Animals; Habenula; Male; Neurons; Nicotine; Rats; Rats Sprague-Dawley; Receptor Serotonin 5-HT2A; SerotoninReceptormedicine.drugAgonistNicotineSerotoninmedicine.drug_classmedia_common.quotation_subjectCentral nervous systemventral tegmental area substantia nigra pars compactaventral tegmental areaNucleus accumbensDentate gyruCatalysisArticleInorganic Chemistry03 medical and health sciencesmental disordersmedicineAnimalsNucleus accumbenPhysical and Theoretical ChemistryMolecular BiologyHabenulabusiness.industryAddictionOrganic ChemistryRats5-HT2CR030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Smoking cessationSprague-DawleySerotoninbusinessReceptors Serotonin 5-HT2030217 neurology & neurosurgerymedial prefrontal cortex
researchProduct

Impairment of Everyday Spatial Navigation Abilities in Mild Cognitive Impairment Is Weakly Associated with Reduced Grey Matter Volume in the Medial P…

2020

Alzheimer’s Disease Neuroimaging Initiative.

0301 basic medicineMalephysiopathology [Cognitive Dysfunction]positron emission tomographypathology [Cognitive Dysfunction]diagnostic imaging [Cognitive Dysfunction]grid cellsAudiologySpatial memoryVolumetry0302 clinical medicinepathology [Gray Matter]Activities of Daily Livingmagnetic resonance imagingEntorhinal CortexGray MatterAged 80 and overGeneral NeuroscienceGgrid cellsCognitionGeneral MedicineHuman brainOrgan SizeMiddle AgedMagnetic Resonance ImagingPsychiatry and Mental healthClinical Psychologymedicine.anatomical_structureFemalediagnostic imaging [Entorhinal Cortex]Spatial NavigationPositron emission tomographymedicine.medical_specialtyphysiology [Spatial Navigation]spatial navigationGrey matter03 medical and health sciencesAtrophymild cognitive impairmentNeuroimagingFluorodeoxyglucose F18medicineHumansCognitive Dysfunctionddc:610Entorhinal cortexAgedvolumetrybusiness.industrydiagnostic imaging [Gray Matter]Mild cognitive impairmentpathology [Entorhinal Cortex]Entorhinal cortexmedicine.disease030104 developmental biologyPositron-Emission TomographyBrodmann area 34Geriatrics and Gerontology18F-fluorodeoxyglucoseAtrophyRadiopharmaceuticalsbusiness030217 neurology & neurosurgeryJournal of Alzheimer's disease : JAD
researchProduct